Skip to main content
Erschienen in: Journal of Artificial Organs 4/2018

24.07.2018 | Original Article

Thrombogenicity and long-term cytokine removal capability of a novel asymmetric triacetate membrane hemofilter

verfasst von: Andreas Körtge, Thomas Wild, Benjamin Heskamp, Manuel Folk, Steffen Mitzner, Reinhold Wasserkort

Erschienen in: Journal of Artificial Organs | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Hemofilters applied in continuous renal replacement therapies (CRRTs) for the treatment of acute kidney injury must meet high standards in biocompatibility and permeability for middle and large molecules over extended treatment times. In general, cellulose-based membranes exhibit good biocompatibility and low fouling, and thus appear to be beneficial for CRRT. In this in vitro study, we compared a novel asymmetric cellulose triacetate (ATA) membrane with three synthetic membranes [polysulfone (PS), polyethersulfone (PES), and polyethylenimine-treated acrylonitrile/sodium methallyl sulfonate copolymer (AN69 ST)] regarding thrombogenicity and cytokine removal. For thrombogenicity assessment, we analyzed the thrombin–antithrombin complex (TAT) generation in human whole blood during 5 h recirculation and filtration. Sieving coefficients of interleukin-6 (IL-6), IL-8, IL-10, and tumor necrosis factor-alpha (TNF-α) were determined using human plasma as test fluid. ATA and AN69 ST membrane permeability were determined also during long-term experiments (48.5 h). ATA exhibited the lowest TAT generation (6.3 µg/L at 5 h), while AN69 ST induced a pronounced concentration increase (152.1 µg/L) and filter clogging during 4 out of 5 experiments. ATA (IL-8: 1.053; IL-6: 1.079; IL-10: 0.898; TNF-α: 0.493) and PES (0.973; 0.846; 0.468; 0.303) had the highest sieving coefficients, while PS (0.697; 0.100; 0.014; 0.012) and AN69 ST (N/A; 0.717; 0; 0.063) exhibited lower permeability. Long-term experiments revealed stronger fouling of the AN69 ST compared to the ATA membrane. We observed the highest permeability for the tested cytokines, the lowest thrombogenicity, and the lowest fouling with the ATA membrane. In CRRT, these factors may lead to increased therapy efficacy and lower incidence of coagulation-associated events.
Literatur
1.
Zurück zum Zitat Ronco C, Ricci Z, Backer D de, Kellum JA, Taccone FS, Joannidis M, et al. Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care. 2015;19:146.CrossRefPubMedPubMedCentral Ronco C, Ricci Z, Backer D de, Kellum JA, Taccone FS, Joannidis M, et al. Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care. 2015;19:146.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27:792–801.CrossRefPubMed Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27:792–801.CrossRefPubMed
4.
Zurück zum Zitat Vriese AS de, Colardyn FA, Philippe JJ, Vanholder RC, Sutter JH de, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999;10:846–53.PubMed Vriese AS de, Colardyn FA, Philippe JJ, Vanholder RC, Sutter JH de, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999;10:846–53.PubMed
5.
Zurück zum Zitat Mueller J, Davis RH. Protein fouling of surface-modified polymeric microfiltration membranes. J Membr Sci. 1996;116:47–60.CrossRef Mueller J, Davis RH. Protein fouling of surface-modified polymeric microfiltration membranes. J Membr Sci. 1996;116:47–60.CrossRef
6.
Zurück zum Zitat Güell C, Davis RH. Membrane fouling during microfiltration of protein mixtures. J Membr Sci. 1996;119:269–84.CrossRef Güell C, Davis RH. Membrane fouling during microfiltration of protein mixtures. J Membr Sci. 1996;119:269–84.CrossRef
7.
Zurück zum Zitat Fujimori A, Naito H, Miyazaki T. Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy. Artif Organs. 1998;22:1014–7.CrossRefPubMed Fujimori A, Naito H, Miyazaki T. Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy. Artif Organs. 1998;22:1014–7.CrossRefPubMed
8.
Zurück zum Zitat Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int. 1999;56:2005–15.CrossRefPubMed Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int. 1999;56:2005–15.CrossRefPubMed
9.
Zurück zum Zitat Pieroni L, Levi Mortera S, Greco V, Sirolli V, Ronci M, Felaco P, et al. Biocompatibility assessment of haemodialysis membrane materials by proteomic investigations. Mol Biosyst. 2015;11:1633–43.CrossRefPubMed Pieroni L, Levi Mortera S, Greco V, Sirolli V, Ronci M, Felaco P, et al. Biocompatibility assessment of haemodialysis membrane materials by proteomic investigations. Mol Biosyst. 2015;11:1633–43.CrossRefPubMed
10.
Zurück zum Zitat Kuragano T, Kuno T, Takahashi Y, Yamamoto C, Nagura Y, Takahashi S, Kanmatsuse K. Comparison of the effects of cellulose triacetate and polysulfone membrane on GPIIb/IIIa and platelet activation. Blood Purif. 2003;21:176–82.CrossRefPubMed Kuragano T, Kuno T, Takahashi Y, Yamamoto C, Nagura Y, Takahashi S, Kanmatsuse K. Comparison of the effects of cellulose triacetate and polysulfone membrane on GPIIb/IIIa and platelet activation. Blood Purif. 2003;21:176–82.CrossRefPubMed
11.
Zurück zum Zitat Liu S, Shi W, Liang X, Su Y, Liang Y, Zhang B, et al. Cellulose triacetate dialyzer reduces platelet loss during continuous veno-venous hemofiltration. Blood Purif. 2010;29:375–82.CrossRefPubMed Liu S, Shi W, Liang X, Su Y, Liang Y, Zhang B, et al. Cellulose triacetate dialyzer reduces platelet loss during continuous veno-venous hemofiltration. Blood Purif. 2010;29:375–82.CrossRefPubMed
12.
Zurück zum Zitat Grooteman MP, Nube MJ, van Limbeek J, van Houte AJ, Daha MR, van Geelen JA. Biocompatibility and performance of a modified cellulosic and a synthetic high flux dialyzer. A randomized crossover comparison between cellulose triacetate and polysulphon. ASAIO J. 1995;41:215–20.CrossRefPubMed Grooteman MP, Nube MJ, van Limbeek J, van Houte AJ, Daha MR, van Geelen JA. Biocompatibility and performance of a modified cellulosic and a synthetic high flux dialyzer. A randomized crossover comparison between cellulose triacetate and polysulphon. ASAIO J. 1995;41:215–20.CrossRefPubMed
13.
Zurück zum Zitat Hoenich NA, Woffindin C, Matthews JN, Goldfinch ME, Turnbull J. Clinical comparison of high-flux cellulose acetate and synthetic membranes. Nephrol Dial Transplant. 1994;9:60–6.PubMed Hoenich NA, Woffindin C, Matthews JN, Goldfinch ME, Turnbull J. Clinical comparison of high-flux cellulose acetate and synthetic membranes. Nephrol Dial Transplant. 1994;9:60–6.PubMed
14.
Zurück zum Zitat Sunohara T, Masuda T. Fundamental characteristics of the newly developed ATA membrane dialyzer. Contrib Nephrol. 2017;189:215–21.CrossRefPubMed Sunohara T, Masuda T. Fundamental characteristics of the newly developed ATA membrane dialyzer. Contrib Nephrol. 2017;189:215–21.CrossRefPubMed
16.
Zurück zum Zitat Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother. 2009;43:1419–25.CrossRefPubMed Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother. 2009;43:1419–25.CrossRefPubMed
17.
Zurück zum Zitat Kutsogiannis DJ, Mayers I, Chin WDN, Gibney RTN. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis. 2000;35:802–11.CrossRefPubMed Kutsogiannis DJ, Mayers I, Chin WDN, Gibney RTN. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis. 2000;35:802–11.CrossRefPubMed
18.
Zurück zum Zitat Opatrny K, Richtrova P, Polanska K, Wirth J, Sefrna F, Brandl M, Falkenhagen D. Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis. Artif Organs. 2007;31:200–7.CrossRefPubMed Opatrny K, Richtrova P, Polanska K, Wirth J, Sefrna F, Brandl M, Falkenhagen D. Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis. Artif Organs. 2007;31:200–7.CrossRefPubMed
20.
Zurück zum Zitat Boyd RF, Zydney AL. Analysis of protein fouling during ultrafiltration using a two-layer membrane model. Biotechnol Bioeng. 1998;59:451–60.CrossRefPubMed Boyd RF, Zydney AL. Analysis of protein fouling during ultrafiltration using a two-layer membrane model. Biotechnol Bioeng. 1998;59:451–60.CrossRefPubMed
22.
Zurück zum Zitat Deppisch R, Storr M, Buck R, Göhl H. Blood material interactions at the surfaces of membranes in medical applications. Sep Purif Technol. 1998;14:241–54.CrossRef Deppisch R, Storr M, Buck R, Göhl H. Blood material interactions at the surfaces of membranes in medical applications. Sep Purif Technol. 1998;14:241–54.CrossRef
Metadaten
Titel
Thrombogenicity and long-term cytokine removal capability of a novel asymmetric triacetate membrane hemofilter
verfasst von
Andreas Körtge
Thomas Wild
Benjamin Heskamp
Manuel Folk
Steffen Mitzner
Reinhold Wasserkort
Publikationsdatum
24.07.2018
Verlag
Springer Japan
Erschienen in
Journal of Artificial Organs / Ausgabe 4/2018
Print ISSN: 1434-7229
Elektronische ISSN: 1619-0904
DOI
https://doi.org/10.1007/s10047-018-1062-1

Weitere Artikel der Ausgabe 4/2018

Journal of Artificial Organs 4/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.